Acute Stroke Treatment
The simultaneous publication of 3 randomized control trials comparing intravenous thrombolysis therapy to the endovascular treatment (EVT) of acute ischemic stroke might have lead to the erroneous conclusion that EVT has no place in the management of acute ischemic stroke. [1] [2] [3] However, careful analysis of these studies shows that these reports have shortcomings because of changes in imaging and device technology and to study designs. 4, 5 These randomized control trials have demonstrated that the EVT is not deleterious for the patients and subgroup analyses in Interventional Management of Stroke III have shown that the EVT can provide some benefits for some patients. Dedicated research in the area of EVT of stroke continues to expand having the goal to optimize devices, techniques, and c-arm-based imaging. The new generation of stent-retrievers has shown great improvement during the earlier technology 6, 7 ; however, further refinements are desired to select patients properly that will benefit from EVT, efficiently transfer those patients selected for EVT to the angiosuite, and to facilitate all aspects of the thrombectomy procedure to provide rapid and complete revascularization.
A potential factor that may contribute to poor clinical outcomes in mechanical thrombectomy is fragmentation of the clot leading to downstream emboli. This has been characterized in vitro, and reduction of distal emboli was achieved using a proximal balloon guide catheter with aspiration during stent-retriever EVT. 8 This experimental approach has been validated by clinical data that show the use of the balloon guide catheter is an independent predictor of good functional outcome at 90 days. 9 Although the role of perfusion computed tomography in triage of acute ischemic stroke is still debated, 10 tremendous advances to perform perfusion imaging with c-arms in the angiosuite have been realized in the past 2 years. C-arm-based cerebral blood volume and cerebral perfusion assessments have evolved to clinical evaluation.
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Intracranial Aneurysm Treatment
Tremendous efforts have been made in the past years to develop new endovascular approaches that will overcome the limitations of the procedure, including aneurysm recanalization and difficulty to treat some complex aneurysms (large and giant, fusiform, or wide-neck aneurysms). 13 Flow diversion has now entered in a more mature phase with the appearance of trials and large series evaluating precisely the safety and efficacy of this technique. Pipeline for Uncoilable or Failed aneurysms (PUFs) trial included 108 patients with aneurysms arising from the internal carotid artery measuring ≥10 mm diameter and a neck ≥4 mm.
14 Complete occlusion at day 180 without major stenosis or use of adjunctive coils was reached in 73.6% of the aneurysms. The primary safety end point (major ipsilateral stroke or neurological death) was reported in 5.6% of patients. A comparison of flow diversion (pipeline embolization device) and coiling in large unruptured intracranial saccular aneurysms showed that the rate of procedure-related complications did not differ between the pipeline embolization device (7.5%) and the coil group (7.5%) and that a significantly higher proportion of aneurysms treated with pipeline embolization device (86%) achieved complete occlusion compared with coiled aneurysms (41%). 15 This high efficacy of flow diverters was confirmed in several multicenter or large single-center series also showing a slightly higher rate of complications or morbidity and mortality compared with PUFs trial. [16] [17] [18] This safety issue is partially explained by 2 emerging complications, which are delayed ruptures and delayed ipsilateral parenchymal hematomas. [19] [20] [21] New flow diverters are now available for aneurysm treatment, including Surpass (Stryker Neurovascular, Fremont, CA) 22 and FRED (Microvention, Tustin, CA). 23 Indications for flow diverter treatment are also expanding.
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Flow disruption is an emerging technique using an intra-aneurysmal device placed at the level of the neck to disrupt the intra-aneurysmal flow and subsequently create intra-aneurysmal thrombosis. Preliminary experience with the WEB shows the great value of this treatment in the management of wide-neck bifurcation aneurysms. [25] [26] [27] Promising advances in the understanding of aneurysm wall biology are important to design future treatment strategies. Similar to vulnerable plaque, inflammation is central to a vascular remodeling process that may lead to ruptureessentially engendering the concept of a vulnerable aneurysm. The Helsinki group recently reported that oxidative stress may be the cause of programmed cell death that is 2
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February 2014 prominent in ruptured human aneurysms. 28, 29 Building on previous work identifying mural cell loss association with rupture, a rat model was developed using decelluarized arterial graft as an aneurysm sac. 30 Pathological analysis demonstrated that thrombus formation within the decelluarized aneurysm could not organize thereby leading to recanalization, inflammation, wall degeneration, and rupture. Similar conclusions on the role of incomplete thrombosis and subsequent inflammatory cell infiltration into the aneurysm wall was confirmed in a swine venous pouch aneurysm model. 31 Ultimately, thorough understanding of aneurysm pathophysiology may enable imaging approaches to identify those at risk of rupture 32 or pharmacological treatment for stabilization. 33 Perhaps the most exciting advances in interventional neuroradiology during the past 2 years involve the imaging system used for EVT. Remarkable radiation dose reduction during diagnostic neuroangiography without sacrificing image quality will benefit patients and operators alike. 34 The decades-long quest to measure blood during angiography may be finally realized with high-frame rate detectors and analysis based on the optical flow algorithm. 35 The first case of deploying a novel microangiographic fluoroscope for aneurysm embolization was reported this year. 36 These developments along with perfusion imaging described above have expanded the capabilities of today's C-arm.
Intracranial and Extracranial Stenting for Atherostenotic Disease
The most recent and final publication on Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) analyzes the long-term benefit of both therapies. 37 The investigators concluded that for high-risk patients with recent stroke associated with a high-grade intracranial stenosis, aggressive medical management is beneficial over stenting using the Wingspan system, and the benefit persists for 3 years. The authors also discuss that the only subgroup that may potentially benefit from stenting include patients with 70% to 99% stenosis who present with ≥2 strokes despite aggressive medical management, and whose last stroke occurred >7 days ago. Selected patients with symptoms related to hypoperfusion (eg, vertebrobasilar insufficiency) may also see a benefit from stenting.
Multiple past randomized clinical trials on carotid artery stenting (CAS), including the European studies Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S), Stent-Protected Angioplasty Versus Carotid Endarterectomy (SPACE), International Carotid Stenting Study (ICSS), and the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), could not show a superiority of stenting over carotid artery surgery. A recently published retrospective survey of carotid artery stenting performed in 8092 patients in Japan during a period of 10 years reports acceptable low incidence of 30-day morbidity and mortality. 38 The rate of major adverse events (stroke, myocardial infarction, or death) at 30 days was varied from 3.5% to 10.2% depending on the distal protection method. The data are excellent and comparable with CEA.
Brain Arteriovenous Malformation
The efficacy and safety of Onyx (Covidien eV3, Irvine, CA) embolization in arteriovenous malformation treatment has been evaluated in a prospective, multicenter, consecutive study (Brain Arteriovenous Malformations Embolisation With Onyx [BRAVO]). 39 The morbidity rate in BRAVO was 5.1%, whereas the mortality was 4.3%.
The long-awaited initial results from A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) are now available. 40 Medical management for brain arteriovenous malformation was compared with interventional therapy, which included surgical resection, embolization, stereotactic radiotherapy, alone or a combination thereof. After enrollment of 223 patients (800 were expected), the data and safety committee stopped the trial as primary end point was reached by 10.1% in the medical arm as compared with 30.7% in the interventional therapy group. The risk of death or stroke was significantly lower in the medical management group (hazard ratio, 0.27; 95% confidence interval, 0.14-0.54). In the interventional therapy arm a higher number of strokes were encountered as compared with medical therapy arm (45 versus 12; P<0.0001) as well as neurological deficits unrelated to stroke (14 versus 1; P=0.0008). The trial will also investigate whether the differences will continue during a follow-up period of next 5 years.
Detailed information for the interventional arm on technical aspects and periprocedural complications has not yet been provided. Unlike BRAVO, the rate of stroke and death in patients that received interventional therapy is high, especially because 68% of patients allocated to interventional therapy presented with Spetzler-Martin grade I or II brain arteriovenous malformation. As the enrollment was nonblinded, brain arteriovenous malformation with anatomic risk factors for hemorrhage, for example, associated aneurysms, deep venous drainage, or venous outflow obstruction, may have been excluded from enrollment. 
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